Pfizer (PFE) Misses Q4 EPS by 6c, Raises FY21 EPS Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $25.39 --0%
EPS Growth %: -56.1%
Financial Fact:
Discontinued operations--net of tax: 0
Today's EPS Names:
MAXN, CSTR, ACU, More
EPS Growth %: -56.1%
Financial Fact:
Discontinued operations--net of tax: 0
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q4 EPS of $0.42, $0.06 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $11.7 billion versus the consensus estimate of $11.43 billion.
GUIDANCE:
Pfizer sees FY2021 EPS of $3.10-$3.20, versus the consensus of $3.19. Pfizer sees FY2021 revenue of $59.4-61.4 billion, versus the consensus of $56.72 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Vail Resorts (MTN) Reports Certain Ski Season Metrics for the Season-to-Date Period Ended April 14
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
